| Name | Title | Contact Details |
|---|
Vantage Oncology is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Manhattan Beach, CA. To find more information about Vantage Oncology, please visit www.vantageoncology.com
Ampersand Health is developing markets, opening clinics and implementing proprietary workflows through investment in the most powerful and efficient mechanism for improving health and reducing costs - primary care. Ampersand Health tailors its solutions for health plans operating in inner city markets serving Medicare Advantage, Managed Medicaid and Dual Eligible members.
PatientPoint powers more effective patient-physician engagements across all points of care. With 30 years of unrivaled experience and continual, meaningful innovation, we are trusted consultants to healthcare providers and sponsoring brands. Using superior analytics and insights, we craft customized programs that drive better engagements. From primary care to complex specialties, from practices to hospitals, PatientPoint provides a cohesive, end-to-end communication platform that enriches the entire care experience and delivers proven results.
Rice Home Medical is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.